The following post from the Ozbiota BlogSpot seems very appropriate:
"A brief summary would be: we're planning and starting several small Ph 1 and 2 trials over the next couple of years and hopefully distract you all from spending around 12 million (annualised) on salaries, general and admin expenses, legals etc.
Which would be great if the market attributed any value to the pipeline, but as you all can see, it doesn't. That might change, but only if and when they are successful. So, the market is heavily discounting this pipeline: it's virtually worthless at present.
Not a single word on LANI in the conference call.
The results release tells us they have not yet completed their brief to the FDA and therefore no request for, or date to, meet with them is yet scheduled.
And nothing on partnering that compound.
LANI is their only current asset worth anything and it appears it won't be in clinical trials this winter.
They are still appealing the USPTO decision on relenza, without explanation. It has been rejected several times, and presumably we are incurring some costs to assist our loyal friends at GSK."
- Forums
- ASX - By Stock
- BTA
- Ozbiota Blogspot
Ozbiota Blogspot
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)